BMX-001 for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Aug 2024: Trial registered, NCT06532279
  2. 23 Jun 2025: Trial started, NCT06532279

The trials

NCT06532279: Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

State
Under way
Phase
Phase 2
People
98 planned
Started
23 Jun 2025
Primary completion
1 Jan 2027
Arms
Arm 2 (BMX-001)
Results
None posted
  1. 1 Aug 2024: Trial registered
  2. 23 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as MnSOD Mimetic BMX-001.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.